Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CRLBF | 6-K | neutral | 5/10 | Cresco Labs filed a management information circular for its October 30, 2026 annual general and special meeting, seeking | Sep 30, 2026 |
| CELU | PRESS-RELEASE | neutral | 4/10 | Celularity highlighted progress at Fontaine Vitale, a regenerative medicine center in Bali, Indonesia, expected to open | Sep 30, 2026 |
| ANIX | CLUSTER | bullish | 5/10 | Four Anixa insiders, including the CEO, President/CFO, and two directors, made open-market purchases totaling $181K over | Sep 30, 2026 |
| LTRN | 424B5 | bearish | 7/10 | Lantern Pharma is raising approximately $3.6 million in net proceeds through a registered direct offering of 1,469,725 s | Sep 30, 2026 |
| QTTB | 8-K | bullish | 6/10 | Q32 Bio presented positive Phase 2a SIGNAL-AA Part B results for bempikibart in alopecia areata at EADV 2026, showing cl | Sep 30, 2026 |
| GDTC | 6-K | bearish | 5/10 | CytoMed Therapeutics reported H1 2026 results showing a net loss of S$1.79 million (US$1.39 million), a 20.1% improvemen | Sep 30, 2026 |
| INDP | 8-K | neutral | 3/10 | Indaptus Therapeutics extended the outside closing date for its previously announced $24.0 million private placement fro | Sep 30, 2026 |
| SLGL | 6-K | neutral | 3/10 | Sol-Gel Technologies announced it will host a KOL Investor Day on October 14, 2026, focused on its lead candidate SGT-61 | Sep 30, 2026 |
| SLXN | 8-K | bullish | 6/10 | Silexion Therapeutics announced the first patient has been dosed in its Phase 2/3 clinical trial of SIL204 for locally a | Sep 30, 2026 |
| QCLS | PRESS-RELEASE | neutral | 3/10 | Q/C Technologies announced a collaboration with Sandia National Laboratories' Center for Integrated Nanotechnologies (CI | Sep 30, 2026 |
| ERNA | PRESS-RELEASE | bullish | 6/10 | Ernexa Therapeutics reported encouraging nonclinical safety results for its lead iPSC-derived cell therapy ERNA-101 acro | Sep 30, 2026 |
| BIAF | 8-K | neutral | 3/10 | bioAffinity Technologies announced it debuted its CyPath Lung test alongside distribution partner AvMEDICAL at the NAVRE | Sep 30, 2026 |
| ANL | 6-K | neutral | 2/10 | Adlai Nortye appointed Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu brings nearl | Sep 30, 2026 |
| RKDA | SC 13G | neutral | 4/10 | MJL Manager LLC (the general partner of Capuchin Capital Fund LP) and its control person Michael Liu have filed a Schedu | Sep 30, 2026 |
| NCNA | 6-K | neutral | 3/10 | NuCana announced that the European Patent Office granted a composition-of-matter patent (EP 3683225) for its anti-cancer | Sep 30, 2026 |
| CADL | PRESS-RELEASE | neutral | 4/10 | Candel Therapeutics presented new biomarker data at ASTRO 2026 showing its lead candidate aglatimagene significantly inc | Sep 30, 2026 |
| EPRX | 6-K | bullish | 6/10 | Eupraxia Pharmaceuticals reported positive 52-week data from the highest dose cohort (Cohort 9) of its Phase 1b/2a RESOL | Sep 30, 2026 |
| AEON | 8-K | bullish | 7/10 | AEON Biopharma received official minutes from its FDA BPD Type 2b meeting for ABP-450 (biosimilar to BOTOX). The FDA agr | Sep 30, 2026 |
| EPRX | PRESS-RELEASE | bullish | 5/10 | Eupraxia Pharmaceuticals announced updated Phase 1b/2a RESOLVE data for EP-104GI in Eosinophilic Esophagitis, showing lo | Sep 30, 2026 |
| SLXN | PRESS-RELEASE | bearish | 7/10 | Silexion Therapeutics dosed the first patient in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer, a | Sep 30, 2026 |
| ABUS | SC TO-I/A | bullish | 6/10 | Arbutus Biopharma announced preliminary results of its $230M modified Dutch auction tender offer, expecting to purchase | Sep 30, 2026 |
| ABUS | PRESS-RELEASE | neutral | 5/10 | Arbutus Biopharma announced preliminary results of its modified Dutch auction tender offer to repurchase up to $230M of | Sep 30, 2026 |
| WVE | PRESS-RELEASE | bullish | 5/10 | Wave Life Sciences announced that GSK selected a candidate from their research collaboration for a hepatology indication | Sep 30, 2026 |
| RFL | 8-K | mixed | 7/10 | Rafael Holdings announced topline results from its pivotal Phase 3 TransportNPC study of Trappsol Cyclo in Niemann-Pick | Sep 30, 2026 |
| MRNA | 8-K | neutral | 3/10 | Moderna announced the appointment of Juan Andres as Chief Operating Officer, a newly created role, effective October 5, | Sep 30, 2026 |
| JBIO | 8-K | neutral | 4/10 | Jade Biosciences announced preclinical data for JADE301, an anti-IFN-β monoclonal antibody for dermatomyositis, showing | Sep 30, 2026 |
| CNTB | 8-K | bullish | 7/10 | Connect Biopharma announced overwhelmingly positive Phase 2 topline data for rademikibart in acute COPD exacerbations wi | Sep 30, 2026 |
| MSLE | 6-K | neutral | 5/10 | Satellos Bioscience announced completion of enrollment in its BASECAMP Phase 2 trial of forazapadin for Duchenne muscula | Sep 30, 2026 |
| TLSA | 6-K | bullish | 5/10 | Tiziana Life Sciences announced it has submitted a request to the FDA for Orphan Drug Designation (ODD) for intranasal f | Sep 30, 2026 |
| MSLE | PRESS-RELEASE | mixed | 6/10 | Satellos Bioscience completed enrollment for BASECAMP, its Phase 2 trial of forazapadin in Duchenne muscular dystrophy, | Sep 30, 2026 |